Circulating CC16 has also been investigated as a biomarker for various diseases, such as asthma [210, 211], ARDS [212], COPD [132, 135], and idiopathic pulmonary fibrosis [213, 214]. Here, SCGB1A1 is linked to pulmonary fibrosis.